NARASARAOPETA INSTITUTE OF PHARMACEUTICAL SCIENCES
Practice School Review-1 Presentation on
PREFORMULATION STUDIES
GUIDED BY :
DR. K.VENKATA GOPAIAH M. Pharm, Ph.D.
Associate Professor
Department of Pharmaceutics
NIPS.
PRESENTED BY:
Name: Shaik Vahedunnisa
Reg no:20CD1R0091
IV-B. Pharmacy
Department of Pharmaceutics
NARASARAOPETA INSTITUTE OF PHARMACEUTICAL SCIENCES
Kotappakonda road, Narasaraopet(M), Palnadu (D) Pin : 522601
2023-24
INTRODUCTION
● Preformulating involves the application of biopharmaceutical
principles to the physicochemical parameters of a drug with the goal of
designing an optimum drug delivery system. [1]
● Each drug substance has intrinsic chemical and physical
characteristics that must be considered before development of a
pharmaceutical formulation.
● So, the characterization of drug molecule is very important step at the
preformulating phase of product development.
DEFINITION
● The word pre - formulation refers to the step to be undertaken
before formulation. It includes determination of physical and
chemical properties of drug substances. Preformulating main goal
is to develop a new drug with safe, stable and effective[1]
ADVANTAGES
● Help in lead identification during drug discovery phase.
● Preformulating provide information regarding degradation
process adverse
condition relevant to the drug.
● Quick and statistically meaningful.
DISADVANTAGES
● Resistance arises from a spherical particle, thus
nanospheres are sized inaccurately.
● Tendency of needle shaped crystal to block the aperture
hole.
● Dissolution of compound in the aqueous conducting
medium.
IMPORTANCE OF
PREFORMULATION
● To form desired quality dosage form.[2]
● To develop an optimum dosage form.
● For targeted drug delivery system.
● To minimize cost of finished product.
● To minimize errors in formulations of dosage form.
GOALS AND OBJECTIVES
● To establish the physio-chemical parameters of a new drug
entity.[2]
● To determine its kinetics and stability.
● To establish its compatibility with common excipients
● To develop optimal drug delivery system
PHYSICAL PROPERTIES
1.Organoleptic characteristics:[3]
● Color, odor, taste of the new drug must be recorded.
2.Physical forms:
● Depending on internal structure compounds is classified as
A.Crystalline (Solid)
B. Amorphous (powder form
Crystalline (Solid):
In crystalline form atoms or molecules are arranged in highly ordered form
and is associated with a three - dimensional array.
Amorphous (powder form):
● In amorphous form atom or molecule are randomly placed
● Solubility & dissolution rate are greater for amorphous form than
crystalline, as amorphous form has higher thermodynamic energy.
Eg. Amorphous form of Novobiocin is well absorbed
Where crystalline form results poor absorption.
POLYMORPHISM
● It is the ability of the compound to crystallize as more than one distinct crystalline species
with different internal lattice. [4]
● Different crystalline forms are called polymorphs
● Polymorphs are of 2 types
A. Enantiotropic
B. Monotropic
● The polymorph which can be changed from one form into another by varying temperature
or pressure is called as Enantiotropic polymorph. Eg. Sulphur.
● One polymorph which is unstable at all temperature & pressure is called as Monotropic
polymorph.
Eg. Glyceryl stearate
DESCRIPTIVE TERM PARTS OF SOLVENT REQUIRED
FOR 1PART OF SOLUTE
Very soluble Less than 1
Freely soluble From 1-10
Soluble From 1-30
Sparingly soluble From 30-100
Slightly soluble From 100-1,000
Very slightly soluble From 1,000-10,000
Practically soluble 10,000 and over
STABILITY ANALYSIS
There are three types of stability analysis
1.Solid state stability
2. Solution state stability
3. Drug - excipient compatibility studies.
CHEMICAL PROPERTIES
1. Hydrolysis
2. Oxidation
3. Reduction
4. Racemization
5. Polymerization.
1.HYDROLYSIS
● If breaking of molecule is due to reaction with water, then it is
called Hydrolysis.[5]
● It is a step in degradation of substance. Drugs such as esters,
amides and lactams undergo hydrolysis.
● Follows second order kinetics.
2.OXIDATION
● Semiconductors can be oxidized by various methods,
including thermal oxidation and plasma enhanced
chemical vapor deposition.
● Among these thermal oxidation is most commonly
used.
● It is a key process in modern silicon technology
● Loss of electron
3.REDUCTION
● Reduction is a relatively more common pathway of drug
metabolic process.
● Hepatic microsomes catalyze diverse reductive chemical
reaction
and require NADPH for this purpose Azo and Nitro reduction is
catalyzed by cytochrome P-450
● Chloral hydrate is reduced to it's active metabolite trichloro
ethanol by alcohol dehydrogenase.
● Gain of electrons.
4.RACEMIZATION
● A Process of conversion of optically active compound into an
optically inactive compound.
● Half of the compound become its mirror images
● Rate of racemization depends in the presence of catalytic
hydrogen, hydroxyl ion, heat, light, temperature and solvent.
● These conversion can make the drug inert
5. POLYMERIZATION
● Polymerization is a form of chemical degradation where
two/more identical molecule combined to form large
complex molecule known as polymers
● It can also be defined as a process in which simple
monomer molecules combined to form large complex.
CONCLUSION
● Preformulation studies on a new drug molecule provide
useful information for subsequent formulations of a
physicochemical stable & bio pharmaceutically suitable
dosage form.
● Preformulation work is the foundation of developing
efficacious and economical formulations.
REFERENCE
1. CH, Popovich GN and Allen VL. Ansel‟s Pharmaceutical Dosage Forms
and Drug Delivery Systems. Lippincott Williams and Wilkins, New York,
2005. P. 042-111.
2. Preformulation in: Aulton ME (Ed). Pharmaceutics -The Science of
Dosage form Design Churchill Livingston; 1996. P. 113-138.
3. The Theory and Practice of Industrial Pharmacy. Lachman L, Lieberman H
A, Joseph L K. 3 rd Ed, Varghese publishing house, Mumbai, 2008 p. 171-
196.Vilegave et. Al., Am. J. Pharmacy & Health Res 2013;1(3) ISSN:
2321-3647 www.ajphr.com 20
4. Absorption of drugs in: Brahmankar DM, Jaiswal SB. Biopharmaceutics
and Pharmacokinetics A treatise.1 st ed. Vallabh Prakashan; 1995. P. 5-
75.
REFERENCE
4. Leon Lachman, Liberman. The theory and practice of Industrial
pharmacy, Edn 4. CBS publishing house, New Delhi.2013 p:217-307.
Banker GS, Rhodes CT. Modern pharmaceutics, Edn 4. Marcel Dekker,
New York. 2002 p:167-184.
5. Loyd V. Allen, Nicholas Popovich, Howard C. Ansel. Ansel’s
pharmaceuticalDosage forms & Drug delivery systems, Edn 8.
B.I.Publication pvt. Ltd, p:187- 193,42 & 43,126-133.
6. Brahmankar D.M, Jaiswal BS. Biopharmaceutics and
pharmacokinetics aTreatise, Edn 2. Vallabh Prakashan, Nagpur. 2009; p:
37-45
formulation Development

formulation Development

  • 1.
    NARASARAOPETA INSTITUTE OFPHARMACEUTICAL SCIENCES Practice School Review-1 Presentation on PREFORMULATION STUDIES GUIDED BY : DR. K.VENKATA GOPAIAH M. Pharm, Ph.D. Associate Professor Department of Pharmaceutics NIPS. PRESENTED BY: Name: Shaik Vahedunnisa Reg no:20CD1R0091 IV-B. Pharmacy Department of Pharmaceutics NARASARAOPETA INSTITUTE OF PHARMACEUTICAL SCIENCES Kotappakonda road, Narasaraopet(M), Palnadu (D) Pin : 522601 2023-24
  • 2.
    INTRODUCTION ● Preformulating involvesthe application of biopharmaceutical principles to the physicochemical parameters of a drug with the goal of designing an optimum drug delivery system. [1] ● Each drug substance has intrinsic chemical and physical characteristics that must be considered before development of a pharmaceutical formulation. ● So, the characterization of drug molecule is very important step at the preformulating phase of product development.
  • 3.
    DEFINITION ● The wordpre - formulation refers to the step to be undertaken before formulation. It includes determination of physical and chemical properties of drug substances. Preformulating main goal is to develop a new drug with safe, stable and effective[1]
  • 4.
    ADVANTAGES ● Help inlead identification during drug discovery phase. ● Preformulating provide information regarding degradation process adverse condition relevant to the drug. ● Quick and statistically meaningful.
  • 5.
    DISADVANTAGES ● Resistance arisesfrom a spherical particle, thus nanospheres are sized inaccurately. ● Tendency of needle shaped crystal to block the aperture hole. ● Dissolution of compound in the aqueous conducting medium.
  • 6.
    IMPORTANCE OF PREFORMULATION ● Toform desired quality dosage form.[2] ● To develop an optimum dosage form. ● For targeted drug delivery system. ● To minimize cost of finished product. ● To minimize errors in formulations of dosage form.
  • 7.
    GOALS AND OBJECTIVES ●To establish the physio-chemical parameters of a new drug entity.[2] ● To determine its kinetics and stability. ● To establish its compatibility with common excipients ● To develop optimal drug delivery system
  • 8.
    PHYSICAL PROPERTIES 1.Organoleptic characteristics:[3] ●Color, odor, taste of the new drug must be recorded. 2.Physical forms: ● Depending on internal structure compounds is classified as A.Crystalline (Solid) B. Amorphous (powder form
  • 9.
    Crystalline (Solid): In crystallineform atoms or molecules are arranged in highly ordered form and is associated with a three - dimensional array. Amorphous (powder form): ● In amorphous form atom or molecule are randomly placed ● Solubility & dissolution rate are greater for amorphous form than crystalline, as amorphous form has higher thermodynamic energy. Eg. Amorphous form of Novobiocin is well absorbed Where crystalline form results poor absorption.
  • 10.
    POLYMORPHISM ● It isthe ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice. [4] ● Different crystalline forms are called polymorphs ● Polymorphs are of 2 types A. Enantiotropic B. Monotropic ● The polymorph which can be changed from one form into another by varying temperature or pressure is called as Enantiotropic polymorph. Eg. Sulphur. ● One polymorph which is unstable at all temperature & pressure is called as Monotropic polymorph. Eg. Glyceryl stearate
  • 11.
    DESCRIPTIVE TERM PARTSOF SOLVENT REQUIRED FOR 1PART OF SOLUTE Very soluble Less than 1 Freely soluble From 1-10 Soluble From 1-30 Sparingly soluble From 30-100 Slightly soluble From 100-1,000 Very slightly soluble From 1,000-10,000 Practically soluble 10,000 and over
  • 12.
    STABILITY ANALYSIS There arethree types of stability analysis 1.Solid state stability 2. Solution state stability 3. Drug - excipient compatibility studies.
  • 13.
    CHEMICAL PROPERTIES 1. Hydrolysis 2.Oxidation 3. Reduction 4. Racemization 5. Polymerization.
  • 14.
    1.HYDROLYSIS ● If breakingof molecule is due to reaction with water, then it is called Hydrolysis.[5] ● It is a step in degradation of substance. Drugs such as esters, amides and lactams undergo hydrolysis. ● Follows second order kinetics.
  • 15.
    2.OXIDATION ● Semiconductors canbe oxidized by various methods, including thermal oxidation and plasma enhanced chemical vapor deposition. ● Among these thermal oxidation is most commonly used. ● It is a key process in modern silicon technology ● Loss of electron
  • 16.
    3.REDUCTION ● Reduction isa relatively more common pathway of drug metabolic process. ● Hepatic microsomes catalyze diverse reductive chemical reaction and require NADPH for this purpose Azo and Nitro reduction is catalyzed by cytochrome P-450 ● Chloral hydrate is reduced to it's active metabolite trichloro ethanol by alcohol dehydrogenase. ● Gain of electrons.
  • 17.
    4.RACEMIZATION ● A Processof conversion of optically active compound into an optically inactive compound. ● Half of the compound become its mirror images ● Rate of racemization depends in the presence of catalytic hydrogen, hydroxyl ion, heat, light, temperature and solvent. ● These conversion can make the drug inert
  • 18.
    5. POLYMERIZATION ● Polymerizationis a form of chemical degradation where two/more identical molecule combined to form large complex molecule known as polymers ● It can also be defined as a process in which simple monomer molecules combined to form large complex.
  • 19.
    CONCLUSION ● Preformulation studieson a new drug molecule provide useful information for subsequent formulations of a physicochemical stable & bio pharmaceutically suitable dosage form. ● Preformulation work is the foundation of developing efficacious and economical formulations.
  • 20.
    REFERENCE 1. CH, PopovichGN and Allen VL. Ansel‟s Pharmaceutical Dosage Forms and Drug Delivery Systems. Lippincott Williams and Wilkins, New York, 2005. P. 042-111. 2. Preformulation in: Aulton ME (Ed). Pharmaceutics -The Science of Dosage form Design Churchill Livingston; 1996. P. 113-138. 3. The Theory and Practice of Industrial Pharmacy. Lachman L, Lieberman H A, Joseph L K. 3 rd Ed, Varghese publishing house, Mumbai, 2008 p. 171- 196.Vilegave et. Al., Am. J. Pharmacy & Health Res 2013;1(3) ISSN: 2321-3647 www.ajphr.com 20 4. Absorption of drugs in: Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics A treatise.1 st ed. Vallabh Prakashan; 1995. P. 5- 75.
  • 21.
    REFERENCE 4. Leon Lachman,Liberman. The theory and practice of Industrial pharmacy, Edn 4. CBS publishing house, New Delhi.2013 p:217-307. Banker GS, Rhodes CT. Modern pharmaceutics, Edn 4. Marcel Dekker, New York. 2002 p:167-184. 5. Loyd V. Allen, Nicholas Popovich, Howard C. Ansel. Ansel’s pharmaceuticalDosage forms & Drug delivery systems, Edn 8. B.I.Publication pvt. Ltd, p:187- 193,42 & 43,126-133. 6. Brahmankar D.M, Jaiswal BS. Biopharmaceutics and pharmacokinetics aTreatise, Edn 2. Vallabh Prakashan, Nagpur. 2009; p: 37-45